alpha defensin 1 (α-defensin 1) antibody and antigen (Recombinant protein)

 Download 

Diagnostic alpha defensin 1 (α-defensin 1) antibodies (anti-alpha defensin 1, anti-α-defensin 1) and antigens (recombinant alpha defensin 1 (α-defensin 1) protein) for Inflammation/autoimmune/inflammatory disease α-defensin 1 detection in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT.

Go to Inflammation/autoimmune/inflammatory disease diagnostics products collection >>

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-h-a-defensin-1-Ag01	alpha defensin 1 (α-defensin 1) antigen	$3090.00
GMP-h-a-defensin-1-Ab01	Anti-human α-defensin 1 mouse monoclonal antibody (mAb)	$1953.00
GMP-h-a-defensin-1-Ab02	Anti-human α-defensin 1 mouse monoclonal antibody (mAb)	$1953.00
GMP-h-a-defensin-1-Ab03	Anti-human α-defensin 1 human monoclonal antibody (mAb)	$1953.00
GMP-h-a-defensin-1-Ab04	Anti-human α-defensin 1 human monoclonal antibody (mAb)	$1953.00

Size： 1mg | 10mg | 100mg

Product Description

Cat No. of Pruducts	GMP-h-a-defensin-1-Ag01
Product Name	alpha defensin 1 (α-defensin 1) antigen
Target/Biomarker	alpha defensin 1 (α-defensin 1)
Alias of Target/Biomarker	DEFA1, DEF1, DEFA2, HNP-1, HP-1, HP1, MRS
Expression platform	synthesized
Isotypes	Peptide Antigen
Bioactivity validation	alpha defensin 1 (α-defensin 1) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in α-defensin 1 level test of Inflammation/autoimmune/inflammatory disease (Prosthetic joint infection (PJI)) and related syndrome evaluation
Products description	Recombinant Human alpha defensin 1 (α-defensin 1) protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (HPLC)
Application	positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation	Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Pruducts	GMP-h-a-defensin-1-Ab01,GMP-h-a-defensin-1-Ab02
Product Name	Anti-human α-defensin 1 mouse monoclonal antibody (mAb)
Target/Biomarker	alpha defensin 1 (α-defensin 1)
Alias of Target/Biomarker	DEFA1, DEF1, DEFA2, HNP-1, HP-1, HP1, MRS
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Human alpha defensin 1 (α-defensin 1) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other alpha defensin 1 (α-defensin 1) antibodies in α-defensin 1 level test of Inflammation/autoimmune/inflammatory disease (Prosthetic joint infection (PJI)) and related syndrome evaluation.
Tag	mFc
Products description	Anti-human α-defensin 1 mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other alpha defensin 1 (α-defensin 1) antibodies.
Reconized/Reactive Species	Human
Purity	Purity: ≥95% (SDS-PAGE)
Application	ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT.
Formulation	Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Pruducts	GMP-h-a-defensin-1-Ab03,GMP-h-a-defensin-1-Ab04
Product Name	Anti-human α-defensin 1 human monoclonal antibody (mAb)
Target/Biomarker	alpha defensin 1 (α-defensin 1)
Alias of Target/Biomarker	DEFA1, DEF1, DEFA2, HNP-1, HP-1, HP1, MRS
Expression platform	CHO
Isotypes	Human lgG1
Bioactivity validation	Human alpha defensin 1 (α-defensin 1) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other alpha defensin 1 (α-defensin 1) antibodies in α-defensin 1 level test of Inflammation/autoimmune/inflammatory disease (Prosthetic joint infection (PJI)) and related syndrome evaluation.
Tag	hFc
Products description	Anti-human α-defensin 1 mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
Reconized/Reactive Species	Human
Purity	Purity: ≥95% (SDS-PAGE)
Application	ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT.
Formulation	Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Target/Biomarker information

Alpha defensins are a family of mammalian defensin peptides of the alpha subfamily. Prosthetic joint infection (PJI) management is not standardized worldwide. Diagnosis of PJI remains challenging because the clinical signs and symptoms and elevation of systemic biomarkers (C-reactive protein, erythrocyte sedimentation rate) may be unclear. Synovial biomarkers have shown encouraging results and they should be used as diagnostic adjuncts to synovial white cell count and culture bacteriology. Synovial leukocyte esterase (LE) and synovial C-reactive protein (CRP) have been evaluated as good screening measures; however, the most promising synovial fluid biomarker in terms of sensitivity and specificity for PJI seems to be alpha defensin (AD). alpha defensin lateral flow test could have its place in ruling in a suspected PJI intraoperatively because of its high specificity and rapid results.

A rare but disastrous consequence of joint replacement surgery is periprosthetic joint infection (PJI). Every year, more than 40,000 people in the US alone are affected by PJI. Once pathogenic bacteria have penetrated the joint implant, they create a biofilm structure that is challenging to remove. Prolonged, intrusive, and expensive procedures are required for the treatment, which frequently has low success rates and raises the risk of fatality and permanent disability. Recent retrospective assessments have highlighted the critical need for quicker and more efficient treatment approaches because the two-stage arthroplasty, which is now the gold standard for treating PJI, takes an average of 16 weeks on average and has a 12-month success rate that is less than 50%.

Blood tests can be somewhat helpful, but cannot diagnose PJI on their own. These tests include the assessment of C-reactive protein and, to a lesser extent, interleukin-6, erythrocyte sedimentation rate, or d-dimer evaluation. These tests don't provide microbiological information and might overlap. About 25% of cases have positive blood cultures, most of which are acute PJI cases. However, the organisms isolated from joint specimens may not necessarily match those discovered in the isolated samples. The main suggested procedure for diagnosing PJI is still a joint aspiration, which needs to be done carefully to prevent cellulitis. For joints other than the knee, particularly the hip, imaging—ideally ultrasound-guided—may be required. Aspirating at least 3.5 milliliters of synovial fluid is necessary to measure the percentage of neutrophils, white blood cells, and culture. Blood tests, such as C-reactive protein measurement and, to a lesser extent, interleukin-6, erythrocyte sedimentation rate, or d-dimer evaluation, may be helpful, but their findings are not sufficient to provide a conclusive diagnosis of peripheral neuropathy. These examinations might coincide, and they don't offer any microbiological insights. Though the isolated organisms may not necessarily coincide with those discovered in joint specimens, positive blood cultures are observed in about 25% of cases, mostly in acute PJI cases. Joint aspiration is still the major suggested procedure for PJI diagnosis; however, it must be done carefully to prevent cellulitis. Joints other than the knee, particularly the hip, may require imaging, ideally ultrasound-guided. To assess the white blood cell count, neutrophil percentage, and other parameters, at least 3.5 milliliters of synovial fluid should be extracted.

Certain cases nevertheless show the diagnostic value of the Alpha(α)-defensin (AD) test. In patients with impaired immune systems, AD demonstrated a 93% sensitivity and 100% specificity in a retrospective investigation. Its sensitivity is, however, reduced in reimplantation situations.

GeneMedi continues to promote the development of PJI diagnostics with its excellent R&D technology and professional team. The highly effective alpha-defensin antibodies it provides have become an important tool in the medical community, providing doctors with a reliable tool to accurately diagnose and track this rare but serious complication. Through continuous innovation and the provision of high-quality products, GeneMedi has brought great help to patients and medical professionals and is expected to make greater contributions to the early detection and effective treatment of PJI.

About GDU